Salubris Pharma gains exclusive rights to GW906 drug

Shenzhen Salubris Pharmaceuticals (SZSE:002294) announced it has entered into an agreement with Gowell Pharma to obtain exclusive licensing rights in mainland China, Taiwan, Hong Kong, and Macau for Gowell Pharma's GW906, an AGT-siRNA drug targeting hypertension. Salubris will be responsible for the drug's development, registration, production, and commercialization in the region. The deal involves upfront and milestone payments totaling up to CNY 180 million, with additional sales milestone payments capped at CNY 37 million. Salubris will also pay Gowell Pharma royalties on future net sales. GW906 is currently undergoing Phase I clinical trials in China. Salubris expects the deal to enhance its pipeline of cardiovascular drugs and improve its competitive position. The agreement is subject to customary government approvals.